Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability-Reference-Cited by-同舟云学术

Arylamine N-acetyltransferase 1 protects against reactive oxygen species during glucose starvation: Role in the regulation of p53 stability

Published:2018-03-08 Issue:3 Volume:13 Page:e0193560
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wang LiLi,Minchin Rodney F.^ORCID,Butcher Neville J.

Funder

National Health and Medical Research Council

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference28 articles.

1. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis;DW Hein;Mutation research,2002

2. Arylamine N-acetyltransferase 1: a novel drug target in cancer development;NJ Butcher;Pharmacological reviews,2012

3. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces E-cadherin up-regulation and cell-cell contact growth inhibition;JM Tiang;PloS one,2011

4. Role for human arylamine N-acetyltransferase 1 in the methionine salvage pathway;KL Witham;Biochemical pharmacology,2017

5. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Molecular cancer research;PJ Adam;MCR,2003

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in CRISPR-Cas systems for colorectal cancer research and therapeutics;Expert Review of Molecular Diagnostics;2024-08-02

2. Small Molecule Inhibitors of Arylamine N-Acetyltransferase 1 Attenuate Cellular Respiration;ACS Pharmacology & Translational Science;2024-07-17

3. Arylamine N-Acetyltransferases;Reference Module in Biomedical Sciences;2024

4. The arylamine N-acetyltransferases as therapeutic targets in metabolic diseases associated with mitochondrial dysfunction.;Pharmacological Reviews;2023-12-07

5. CRISPR/Cas9 as a therapeutic tool for triple negative breast cancer: from bench to clinics;Frontiers in Molecular Biosciences;2023-07-04